![Child Front Child Front](http://brainblogger.com/wp-content/uploads/Child-Front-300x414.jpg)
Our first post delineated the five erroneous myths often adhered to when prescribing youth’s psychotropic medication. Here are the three areas of recommended research to address this “alarming” problem.
1) Clarify child/adult differences for psychotropics. The future promises to see questionnaires and interviews tailored specifically to children and adolescents. Prominent will be the initiation of normative data for youth mental disorders. Studies will need to focus on specific age groups, disorders and treatments.
2) Attend to the growth of “cosmetic” use of psychotropics in children and adolescents. Researchers’ alarm over the marked increase in psychotropic prescriptions for youth has spilled over into the public arena. Recent media attention, in conjunction with changes in clinical practice standards and drug product labeling, has juggernauted psychotropic investigation to the forefront of the research agenda.
3) Address concerns about the diagnostic validity of mental illness in the current DSM classification system. Due to lack of psychotropic research on youth, the current DSM system is flawed, Lakhan and Hagger-Johnson noted. Ethical challenges such as reluctance to enroll children in psychotropic clinical trials and the lack of “well-designed”, placebo-controlled trials have traditionally been barriers to effective research. Increasingly, the idea of hands-on research with children is more palatable.
Lakhan and Haggar-Johnson remind us that “for the first time, we can begin to record and measure, rather than assume, the impact of prescribed psychotropics on children and adolescents.” The final verdict — children and adolescents need accurate, age-appropriate data that does not exist today.
Reference
Lakhan, S., & Hagger-Johnson, G. (2007). The impact of prescribed psychotropics on youth Clinical Practice and Epidemiology in Mental Health, 3 (1) DOI: 10.1186/1745-0179-3-21
7 Responses
kindly look for more details on the advertisements
I wrote on this issue for The Lancet Student last year:
You can read the full article here. I would like to know the public’s opinion on traditional clinical trials or using virtual models for testing medications on pediatric patients. Thank you.
Sincerely,
Shaheen